ELUTIA INC.
ELUTNasdaq
$0.95
0.0%Jul 17 close · end-of-day
Price
1Y↓ -53.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$40.8M
Enterprise Value
$12.4M
P/E
1.0
P/S
3.3
P/B
1.8
EV/EBITDA
—
PEG
—
FCF Yield
-112.2%
Dividend Yield
—
Revenue (TTM)
$12.5M
Net Income (TTM)
$49.8M
Free Cash Flow (TTM)
-$45.8M
Gross Margin
56.3%
Operating Margin
-212.6%
Net Margin
400.2%
ROE
221.3%
ROIC
—
Debt / Equity
—
Net Cash
$28.5M
Return 1Y
-53.2%
Company profile
Aziyo Biologics, Inc. focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device.
- CEO
- Charles R. Mills
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 180
- Headquarters
- Maryland
- Website
- aziyo.com
Management & directors
- Mills C RandalPRESIDENT AND CEO
- Ferguson MatthewCHIEF FINANCIAL OFFICER
- Williams Michelle LerouxCHIEF SCIENTIFIC OFFICER
Roles derived from SEC Form 4 filings.
Earnings
ELUT Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$3.1M↑ +5.5%
Diluted EPS-$0.17↓ -19.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $42.7M | $20.5M | $23.8M | $24.7M | $14.5M | $12.3M |
| Gross profit | $20.6M | $9.3M | $11.6M | $11.1M | $6.7M | $6.6M |
| Operating income | -$13.6M | -$28.5M | -$35.2M | -$30.5M | -$30.7M | -$26.9M |
| Net income | -$21.8M | -$24.8M | -$32.9M | -$37.7M | -$53.9M | $53.4M |
| Diluted EPS | -$8.88 | -$2.38 | -$2.38 | -$2.07 | -$1.86 | $0.87 |
| Operating cash flow | -$13.6M | -$15.4M | -$21.4M | -$21.8M | -$22.7M | -$44.8M |
| Free cash flow | -$14.3M | -$15.8M | -$22.0M | -$22.1M | -$23.3M | -$46.7M |
| Gross margin | 48.2% | 45.4% | 48.8% | 44.7% | 46.4% | 53.7% |
| Operating margin | -31.9% | -139.5% | -147.5% | -123.4% | -212.3% | -218.9% |
| Net margin | -51.1% | -121.4% | -137.9% | -152.2% | -372.9% | 434.2% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.3M | $3.7M | -$2.2M | $3.0M | $6.3M | $3.3M | -$244,000.00 | $3.1M |
| Gross profit | $2.8M | $1.8M | -$718,000.00 | $1.4M | $3.1M | $1.9M | $303,000.00 | $1.8M |
| Operating income | -$8.5M | -$9.2M | -$4.5M | -$6.8M | -$9.9M | -$5.2M | -$5.1M | -$6.3M |
| Net income | -$28.2M | $1.3M | -$9.1M | -$3.9M | -$9.6M | -$3.9M | $70.8M | -$7.5M |
| Diluted EPS | -$1.13 | -$0.33 | $0.35 | -$0.21 | -$0.26 | -$0.19 | $1.53 | -$0.17 |
| Operating cash flow | -$4.3M | -$3.4M | -$12.3M | -$8.9M | -$8.2M | -$2.9M | -$24.8M | -$7.8M |
| Free cash flow | -$4.3M | -$4.0M | -$12.4M | -$9.2M | -$8.3M | -$3.5M | -$25.7M | -$8.3M |
| Gross margin | 44.5% | 48.9% | 32.9% | 46.8% | 48.8% | 55.8% | -124.2% | 57.9% |
| Operating margin | -135.3% | -250.5% | 208.6% | -229.7% | -157.7% | -156.7% | 2070.1% | -203.9% |
| Net margin | -447.9% | 35.1% | 415.6% | -133.3% | -153.4% | -116.4% | -29012.7% | -239.9% |
Company news
Jul 16, 2026
- 4d agoCellution Biologics Inc. Signs Definitive Agreement to Acquire SimpliDerm® Human Hydrated Acellular Dermal Matrix Business from Elutia Inc., Expanding its Allograft Portfoliofinance.yahoo.com
- 4d agoElutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launchfinance.yahoo.com
May 18, 2026
May 15, 2026
May 14, 2026
- 67d agoElutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery Marketfinance.yahoo.com
- 67d agoElutia to Present at the 16th Annual LD Micro Invitational on May 18thfinance.yahoo.com
- 67d agoElutia to Present at the 16th Annual LD Micro Invitational May 18thfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-21 | Mills C Randal· PRESIDENT AND CEO | Tax withholding | 8,064 | $1.06 | $8,547.84 | filing |
| 2026-06-21 | Mills C Randal· PRESIDENT AND CEO | Option exercise | 22,473 | — | — | filing |
| 2026-06-10 | Mills C Randal· PRESIDENT AND CEO | Tax withholding | 9,718 | $1.04 | $10,106.72 | filing |
| 2026-06-10 | Ferguson Matthew· CHIEF FINANCIAL OFFICER | Tax withholding | 4,485 | $1.04 | $4,664.40 | filing |
| 2026-06-10 | Williams Michelle LeRoux· CHIEF SCIENTIFIC OFFICER | Tax withholding | 4,269 | $1.04 | $4,439.76 | filing |
| 2026-06-10 | Williams Michelle LeRoux· CHIEF SCIENTIFIC OFFICER | Option exercise | 12,500 | — | — | filing |
| 2026-06-10 | Ferguson Matthew· CHIEF FINANCIAL OFFICER | Option exercise | 12,500 | — | — | filing |
| 2026-06-10 | Mills C Randal· PRESIDENT AND CEO | Option exercise | 27,083 | — | — | filing |
| 2026-06-01 | RAKIN KEVIN | Gift | 70,000 | $0.00 | $0.00 | filing |
| 2026-06-01 | RAKIN KEVIN | J | 50,000 | $0.00 | $0.00 | filing |
| 2026-03-10 | Mills C Randal· PRESIDENT AND CEO | Tax withholding | 11,100 | $1.09 | $12,099.00 | filing |
| 2026-03-10 | Ferguson Matthew· CHIEF FINANCIAL OFFICER | Tax withholding | 5,123 | $1.09 | $5,584.07 | filing |
| 2026-03-10 | Williams Michelle LeRoux· CHIEF SCIENTIFIC OFFICER | Tax withholding | 4,613 | $1.09 | $5,028.17 | filing |
| 2026-03-10 | Mills C Randal· PRESIDENT AND CEO | Option exercise | 27,084 | — | — | filing |
| 2026-03-10 | Williams Michelle LeRoux· CHIEF SCIENTIFIC OFFICER | Option exercise | 12,500 | — | — | filing |
| 2026-03-10 | Ferguson Matthew· CHIEF FINANCIAL OFFICER | Option exercise | 12,500 | — | — | filing |
| 2026-01-30 | RAKIN KEVIN | Buy | 70,000 | $1.06 | $74,200.00 | filing |
| 2026-01-30 | NEELS GUIDO J | Buy | 20,000 | $1.04 | $20,800.00 | filing |
| 2026-01-29 | NEELS GUIDO J | Buy | 15,000 | $1.06 | $15,900.00 | filing |
| 2026-01-28 | NEELS GUIDO J | Buy | 15,000 | $1.06 | $15,900.00 | filing |
| 2025-12-17 | Ferguson Matthew· CHIEF FINANCIAL OFFICER | Buy | 60,000 | $0.53 | $31,800.00 | filing |
| 2025-12-17 | RAKIN KEVIN | Buy | 50,000 | $0.52 | $25,995.00 | filing |
| 2025-12-17 | Makes Brigid | Buy | 25,000 | $0.52 | $13,000.00 | filing |
| 2025-12-17 | Colpman David | Buy | 12,500 | $0.51 | $6,375.00 | filing |
| 2025-12-17 | Mills C Randal· PRESIDENT AND CEO | Buy | 3,000 | $0.51 | $1,530.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.